Statistics show that about ten percent of the people in the United Kingdom are with pre-diabetes. Within ten years, five to ten percent of the people with pre-diabetes may progress into diabetes. Pre-diabetes is easy to cure with the diet, exercise and lifestyle changes but it is difficult to cure diabetes.
A study at the Imperial College, London, United Kingdom shows the prevention of pre-diabetes (also known as "borderline diabetes") with the usage of Liraglutide diabetes drug along with the diet and exercise program. Liraglutide diabetes drug increases a hormone which can suppress the appetite in the gut. A study was conducted to find out the effects of a self-administered injection of Liraglutide along with diet and exercise program for the prevention of diabetes on 2,254 obese people with pre-diabetes. After three years, the study shows.
Liraglutide is a diabetes drug to manage type 2 diabetes (T2D). But the success of the Liraglutide in preventing type 2 diabetes (T2D) is very interesting. Co-author of the study says that the Liraglutide drug mimics the action of GLP-1, a hormone produced naturally in our body to suppress and regulate appetite.
This study was funded by Novo Nordisk. The co-author of the study was Le Roux, Department of Medicine, Imperial College, London, United Kingdom and the study was published in the Lancet.
A study shows the risk of dementia later in the life of the middle age people (between 45 and 64 years) with the heart disease. A 25-year follow-up study to find out the association between vascular risk factors and the risk of dementia has found a higher risk of dementia in old, less educated and black people with hypertension, smoking, diabetes and in people carrying with the e4 version of the APOE gene.
The researchers say that the current study is an observational study and the study did not find out the changes in the future risk of dementia by treating the risk factors associated with the heart disease. Authors of the study are Gottesman RF, Albert M and Coker L. The study was presented at the 2017 International Stroke Conference in Houston.
A recent study shows Jardiance diabetes drug has the power to reduce the blood sugar (glucose) levels and cardiovascular diseases. The Australian study has got an approval to prescribe the Jardiance diabetes drug for the treatment of cardiovascular diseases in the patients with type 2 diabetes (T2D).
The Therapeutic Goods Administration, a regulatory body for therapeutic goods, Department of Health, Australia has listed the Jardiance drug under the medicines for the treatment of cardiovascular diseases in the patients with type 2 diabetes. Jardiance is a sodium glucose co-transporter 2 inhibitor (SGLT2) drug. This drug prevents excess glucose (sugar) levels in the blood by blocking the reabsorption of sugar (glucose) in the kidney from urine.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.